SANTA
CLARA, Calif., Feb. 21,
2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq:
SMLR), a company that develops, manufactures and markets innovative
medical products and services that assist in evaluating and
treating chronic diseases, today announced that it will report
financial results for the fourth quarter and full year ended
December 31, 2023, after the close of
U.S. financial markets on Tuesday, March 5,
2024. Doug Murphy-Chutorian,
M.D., chief executive officer of Semler Scientific, will host a
conference call at 4:30 pm ET the
same day. Renae Cormier, chief
financial officer, and Jennifer
Oliva-Herrington, chief operating officer, will join him on
the call.
We encourage participants to pre-register for the conference
call using the following
link: https://dpregister.com/sreg/10185342/fb4eeec618. Callers
who pre-register will be given a conference passcode and unique PIN
to gain immediate access to the call and bypass the live operator.
Participants may pre-register at any time, including up to and
after the call start time.
Those without internet access or unable to pre-register may dial
in by calling:
Domestic callers: 833-816-1161
International
callers: 412-317-0717
Please specify to the operator that you would like to join the
"Semler Scientific Call." The conference call will be archived on
Semler Scientific's website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler
Scientific, Inc. develops, manufactures and markets
innovative products and services that assist in evaluating and
treating chronic diseases. Its flagship product,
QuantaFlo®, which is patented and cleared by the U.S. Food
and Drug Administration (FDA), is a rapid point-of-care test that
measures arterial blood flow in the extremities. The
QuantaFlo® test aids in the diagnosis of cardiovascular
diseases, such as peripheral arterial disease (PAD), and
Semler Scientific is seeking a new 510(k)
clearance for expanded indications. QuantaFlo® is used
by healthcare providers to evaluate their patient's risk of
mortality and major adverse cardiovascular events (MACE).
Semler Scientific has a minority investment in
Mellitus, SYNAPS Dx, as well as Monarch Medical
Technologies LLC, a privately held company whose product
EndoTool® offers a technological solution for
inpatient glycemic management. Additional information
about Semler Scientific can be found at
www.semlerscientific.com.
CONTACT:
Renae Cormier, CFO
ir@semlerscientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-to-report-fourth-quarter-and-year-end-2023-financial-results-and-host-conference-call-on-march-5-2024-302067128.html
SOURCE Semler Scientific, Inc.